Business Wire

CA-ALATION/BIGEYE/SODA

Share
Alation Forges Strategic Partnerships With Bigeye and Soda

Alation, Inc. , the leader in enterprise data intelligence solutions, today announced formal partnership agreements with Bigeye and Soda , leading data observability vendors. The partnerships provide customers with the choice to select the best data observability partner for their organisation’s needs.

Alation’s active data governance helps organisations drive data culture by providing all data users, regardless of technical skillset, with access to quality data. Bigeye’s data observability platform helps detect data quality issues and ensures reliable data pipelines. Soda’s data observability platform allows teams to discover, prioritise, and collaboratively resolve data issues. The platforms are invaluable for alerting technical users to deeper data quality issues, such as the trustworthiness of the data or its usability. Alation’s integrations with Bigeye and Soda provide all data consumers, from business users to data scientists, with a single-pane-of-glass view into the trustworthiness and reliability of data. This results in a streamlined analysis process that empowers data users to use data and generate insights with confidence.

“When it comes to data intelligence and data governance, Alation has long catered to the needs of every user, not just the technical user. Our customers see Alation as the primary source of reference for all metadata, which enables all teams across an organisation to make data-driven business decisions,” said Raj Gossain, Chief Product Officer, Alation. “The Alation Data Catalog is a platform known for its interoperability. With our APIs and partnerships, we continue to expand the ecosystem of companies that work with Alation, giving our customers a modern user experience that seamlessly integrates best-of-breed solutions that meet their needs.”

Fuelled by exponential data growth and expanding privacy regulations, data governance is a top priority for enterprises. Traditional approaches to data governance have long focused on restrictive data policies and procedures that hinder adoption and result in additional challenges for those responsible for the data. Effective data governance programs must focus on enabling users to leverage trusted, governed data to make informed, data-driven decisions. Organisations using an active, people-first approach to data governance, drive data culture and put quality data, not just any data, in everyone’s hands.

“A key part of ensuring data quality and reliable data pipelines is the ability to keep data teams and data consumers on the same page. With the integration between Alation and Bigeye, everyone — from data engineers all the way to business analysts — has a clear understanding of the health of the data,” said Egor Gryaznov, CTO and cofounder, Bigeye. “Pairing the leading data observability platform with Alation’s leading data catalog provides organisations with a holistic view of the quality of their data.”

“The modern data catalog is becoming a real-time, operational system that's deeply tied into an organisation’s data ecosystem. For metadata, that means it is purposefully built into every step of the data value chain, as opposed to it being an afterthought. This allows data teams to truly see what's happening so that they can catch data issues before they reach consumers downstream,” explains Maarten Masschelein, CEO and Co-Founder, Soda. “Through our partnership with Alation, users can discover and understand the data that matters to them, and trust they are working with data that is verified, reliable, and governed. Soda enables data producers and consumers to agree on what good data looks like by combining both machine learning-based alerting, as well as rules-based testing and validation of data. Every single operational metadata quality issue that Soda captures, can be made natively available in the Alation Data Catalog. We layer our data quality controls on top of Alation’s automated lineage to make it easy to do Root Cause Analysis (RCA), as well as assess the upstream and downstream impact of a data issue.”

To learn more about Alation’s partnerships with Bigeye and Soda:

About Alation
Alation is the leader in enterprise data intelligence solutions including data search & discovery, data governance, data stewardship, analytics, and digital transformation. Alation’s initial offering dominates the data catalog market. Thanks to its powerful Behavioral Analysis Engine, inbuilt collaboration capabilities, and open interfaces, Alation combines machine learning with human insight to successfully tackle even the most demanding challenges in data and metadata management. More than 300 enterprises drive data culture, improve decision making, and realise business outcomes with Alation including AbbVie, American Family Insurance, Cisco, Exelon, Fifth Third Bank, Finnair, Munich Re, NASDAQ, New Balance, Parexel, Pfizer, US Foods and Vistaprint. Headquartered in Silicon Valley, Alation was named to Inc. Magazine’s Best Workplaces list and is backed by leading venture capitalists including Blackstone, Costanoa, Data Collective, Dell Technologies, Icon, ISAI Cap, Riverwood, Salesforce, Sanabil, Sapphire, and Snowflake Ventures. For more information, visit alation.com .

About Bigeye
Bigeye is the leading data observability platform designed to help data teams build trust in data. Data teams use Bigeye to instrument their data with monitoring, detect anomalies, and publish SLAs for their stakeholders to know the health of the data at all times and ensure reliable data pipelines. Complete API access, a user-friendly interface, and flexible customisation options help data teams work the way they want to. Bigeye can be deployed in as little as 15 minutes and uses automation and anomaly detection to help teams monitor all aspects of their data quality, proactively detect and resolve issues, and ensure that every user can trust the data. www.bigeye.com

About Soda
Soda is the data monitoring platform that keeps your data fit for purpose, verifiable and trustworthy. We uncover data issues, alert the right teams, and trigger resolution workflows to identify causes that impede data quality. Our open source testing projects and monitoring platform brings together data engineers, operations and the business to create trusted data. Data-driven organisations choose Soda to realise the value of their data and secure its quality. For more information, visit www.soda.io .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release

Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release

Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release

- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o

SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye